SARS-CoV-2 (COVID-19) siRNA panel*

The COVID-19 virus is rapidly spreading around the world with devastating consequences on virtually every aspects of peoples social and economic life providing a major threat to public health. To fight that situation and better understand the biology of Corona virus infections research tools are required that are proven and tested. Eupheria Biotech developed the esiRNA technology (endoribonuclease-prepared siRNAs), that provides highly specific knockdown of transcripts by RNA interference. With longstanding expertize in the functional characterization of genes, Eupheria adapted the esiRNA technology to target host-virus factors for SARS-CoV-2 and genes involved in intracellular virus progression. We also included target genes that were found to be responsible for the infection with other coronavirus strains such as SARS-CoV and MERS. We offer this panel as a fully customizable esiFLEX option in a 96-well format at scales of 5.0 µg sufficient for screening divers human cell lines. Additional genes can be added at free choice and single targets can be ordered as individual esiRNAs. Our COVID-19 gene panel of esiRNAs is the prefect research tool for fast and easy screening and rapid identification of host-virus factors. For more information visit our esiRNA product page and see our Tools & Resource Section “How to handle your esiRNA” for recommendations concerning transfection conditions in different cell lines. Our technical support will help you with inquiries and any further questions you may have at info©eupheria.com.

*Please note, that we cannot guarantee the completeness of this panel at this stage and that those chosen genes are in part based on preliminary reports, that have not gone through the peer-reviewed process due to the current circumstances.

Specifications

All esiRNAs were designed based on the sequence annotations from the ENSEMBL database.

Quality Control: esiRNAs are designed using the DEQOR design algorithm. The PCR products used for production are tested via gel electrophoresis and identity is confirmed by DNA sequencing. Quality of esiRNA is validated by gel electrophoresis and concentrations are determined by measuring OD260 or fluorescence intensity.

Purification: RNaseIII-digested products are purified via column purification using anion-exchange chromatography, precipitated with isopropanol and washed with ethanol.

 

Format: All esiRNA are delivered in solution (resuspended in nuclease-free TE buffer) normalized to 50 ng/µl.

Storage and Stability: esiRNAs stored at -20°C are stable for 2 years. No decrease in stability was observed after 12 freeze/thaw cycles.

Shipment: Shipped in solution on dry ice in sealed 96-well plates.

Technical Data Sheet: The COVID-19 panel will be delivered with a CD containing the technical data sheet, which includes the plate number and positions of esiRNAs, the esiRNA ID numbers, organism, amount (µg), concentration, lot #, and target sequence.